Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 05, 2021 11:11am
61 Views
Post# 33131913

RE:TH vs CYDY

RE:TH vs CYDYCYDY insider ownership is over 8% held by institutional investors 0.12% versus THTX 1.2% and over19% held by institutions.
Their daily average volume is over 4 million versus THTX's about 100k.So their trades comes mostly from retail investors why?
Because they early in the process saw the retail opportunity and surfed the retail tsunami well while THTX stubbornly refused to tap into that market. 


jeffm34 wrote:

TH would have to be trading at over $20 cnd to equal the market cap of CYDY.  Cytodyne has 1 drug candidate in trials which if successful they hope will compete with Trogarzo. They already gave away 50% of their potential sales in a commercialization deal.  The Covid trials are just a PR stunt. They have dozens of class action lawsuits pending against them. Last year end they lost over $100M and had zero revenue with about 15M cash. 

TH already has 2 drugs producing sales, an oncology program with a massive potential market and a phase 3 NASH program. Yet we trade at 1/5 of what CYDY trades at. That tells you everything you need about the ability of our current BOD and management to get a real story out to the right people. 



<< Previous
Bullboard Posts
Next >>